AN ACT to amend Tennessee Code Annotated, Title 53 and Title 68, relative to relative to drug labels.
SB1031, enacted as Public Chapter No. 108, creates the “Restore Trust in Public Health Messaging Act” and adds a new part to Tennessee Code Annotated Title 68. The bill restricts the Tennessee Department of Health, the commissioner of health, local health departments, and the state executive branch from directly or indirectly promoting, distributing, or endorsing information about FDA-regulated vaccines, masks, or emergency-use-authorized products if that information conflicts with FDA-approved or FDA-authorized labeling, or if it suggests safety or effectiveness for coadministration without adequate clinical trials. It also applies to communications funded by state or federal grants distributed by the state and covers both product-specific and general-category messaging.
The act requires the commissioner and state executive branch to establish an internal review process by July 1, 2025, to ensure compliance with FDA labeling standards in communications, educational materials, and public health campaigns. It also requires annual reporting to the attorney general and legislative officials beginning January 15, 2026, and authorizes the attorney general to receive complaints, investigate suspected violations and retaliation, and assess penalties. If a violation is found, the responsible entity may be required to stop dissemination, issue a correction notice, and remove nonconforming public materials by January 15, 2026.
The bill’s impact on state law is to impose new limits on public-health messaging by state and local health entities and to create enforcement mechanisms tied to the attorney general. It authorizes disciplinary action against employees or agents who violate the act and allows civil penalties against entities receiving state-related funds, including penalties up to three times the amount of state resources misused or $50,000, whichever is greater, along with possible ineligibility for grants or inducements for one to ten years. The law takes effect immediately upon becoming law.
The general sentiment reflected in the available voting history suggests the bill had enough support to advance, with the Senate Health and Welfare Committee recommending passage by a 6-1 vote. No committee transcript is available here, so the record does not show detailed debate, but the structure of the bill indicates a strong policy interest in constraining public-health communications to align closely with FDA labeling and authorization language.
The main points of contention likely center on whether the bill protects the public from misleading health information or instead restricts state and local health officials’ ability to communicate about vaccines, masks, and emergency-use products during public health emergencies. Potential concerns include the breadth of the prohibition, the inclusion of indirect promotion through grants or inducements, the treatment of general-category statements, and the enforcement role given to the attorney general. The bill expressly preserves the ability of officials to criticize FDA decisions, which may have been intended to address free-speech or policy concerns.
This act adds a new regulatory framework in Title 68 governing public-health communications by state and local health entities. It limits what the Department of Health, local health departments, and the state executive branch may say about FDA-regulated vaccines, masks, and emergency-use-authorized products, and it creates compliance, reporting, correction, removal, and penalty provisions enforced through the attorney general. It also affects recipients of state-distributed or state-influenced funds by requiring removal of nonconforming materials and exposing violators to civil penalties and funding ineligibility.
The available vote history indicates generally favorable sentiment toward the bill, as it passed the Senate Health and Welfare Committee 6-1 with two members present not voting. With no transcript provided, there is no direct record of debate, but the committee result suggests the measure was viewed by most members as a permissible or desirable response to public-health messaging concerns. The narrow opposition implied by the single no vote suggests at least some concern about the bill’s scope or enforcement.
The likely contention is between supporters who view the bill as a safeguard against misleading or inconsistent public-health messaging and opponents who may see it as a restriction on public-health agencies’ discretion and communication flexibility. Specific flashpoints include the prohibition on information that does not match FDA labeling, the ban on claims about coadministration without adequate trials, the requirement to remove existing materials, and the civil and employment penalties. The bill’s carve-out allowing criticism of FDA decisions may have been intended to soften concerns, but the breadth of the restrictions and the attorney general’s enforcement authority remain the most notable issues.